Vitamin D and Prostate Cancer

Experimental Biology and Medicine

Volumn 229, Issue 4, 2004, Pages 277-284

  Stewart, LaMonica V ^a   Weigel, Nancy L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen receptor; Apoptosis; Cell cycle; Growth factors; Prostate; Vitamin D

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXERCALCIFEROL; LG 190119; MITOXANTRONE; RO 25 6760; RO 25 6860; SEOCALCITOL; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER RISK; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG SCREENING; HUMAN; HYPERCALCEMIA; IN VIVO STUDY; NONHUMAN; PROSTATE CANCER; SHORT SURVEY; SIDE EFFECT; XENOGRAFT;

RODENTIA;

EID: 1642357671     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422900401     Document Type: Short Survey

References (98)

1. American Cancer Society. Cancer Facts and Figures 2003, 2003.
2. Santen R. Clinical review 37: endocrine treatment of prostate cancer. J Clin Endocrinol Metab 75:685-689, 1992.
3. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 78:1193-1231, 1998.
4. 3. Cancer Epidemiol Biomarkers Prev 7:391-395, 1998.
5. Haussler M, Mangelsdorf DJ, Komm BS, Terpening CM, Yamazaki K, Allegretto EA, Baker AR, Shine J, McDonnell TJ, Hughes M, Weigel NL, O'Malley BW, Pike JW. Molecular biology of the vitamin D hormone. Recent Prog Horm Research 44:263-305, 1988.
6. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810, 1994.
7. 3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 170:609-618, 2001.
8. Krill D, Stoner J, Konety BR, Becich MJ, Getzenberg RH. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology 54:171-177, 1999.
9. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9:265-270, 2000.
10. 2 as therapeutic agents for prostate cancer. Clin Cancer Res 6:901-908, 2000.
11. Konety BR, Leman E, Vietmeier B, Arlotti J, Dhir R, Getzenberg RH. In Vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate. J Urol 164:1812-1818, 2000.
12. 3-induced growth inhibition. Cancer Res 61:2852-2856, 2001.
13. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 10:1307-1311, 1990.
14. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70:2861-2869, 1992.
15. 3. J Clin Invest 76:1536-1538, 1985.
16. Matsuoka L, Wortsman J, Haddad J, Kolm P, Hollis B. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 127:536-538, 1991.
17. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472, 1993.
18. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6:235-239, 1995.
19. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5: 121-126, 1996.
20. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9:425-432, 1998.
21. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11:847-852, 2000.
22. Whitlatch L, Young M, Schwartz G, Flanagan J, Burnstein K, Lokeshwar B, Rich E, Holick M, Chen T. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81: 135-140, 2002.
23. 3. Cancer Res 52:515-520, 1992.
24. 1. Endocrinology 138:1491-1497, 1997.
25. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993.
26. 1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 144:50-60, 2003.
27. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141:2548-2556, 2000.
28. 3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem 269:23750-23756, 1994.
29. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 277: F157-175, 1999.
30. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277-288, 1996.
31. 3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137:1554-1561, 1996.
32. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90, 1997.
33. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-3298, 1997.
34. Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol 186:69-79, 2002.
35. Rao A, Woodruff R, Wade W, Kute T, Cramer S. Genistein and vitamin D synergistically inhibit prostatic epithelial cell growth. J Nutr 132:3191-3194, 2002.
36. 1 accumulation. Endocrinology 139:1197-1207, 1998.
37. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17, 2000.
38. Zetterberg A, Larsson O, Wiman KG. What is the restriction point? Curr Opin Cell Biol 7:835-842, 1995.
39. 3. Int J Oncol 8:41-47, 1996.
40. Yang E, Burnstein K. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 287:46862-46868, 2003.
41. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 61:7122-7129, 2001.
42. Bartek J, Lucas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490:117-122, 2001.
43. Jensen S, Madsen M, Lukas J, Binderup L, Bartek J. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370-1380, 2001.
44. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59:4848-4856, 1999.
45. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 276: 9101-9107, 2000.
46. 3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235:539-544, 1997.
47. 3 on proliferation of cancer cells in vitro. Cancer Lett 120:65-69, 1997.
48. 3 in prostate cancer. Mol Cancer Ther 1:667-677, 2002.
49. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566, 1998.
50. Platz E, Pollak M, Rimm E, Majeed N, Tao Y, Willett W, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8:1107-1110, 1999.
51. Chokkalingam A, Pollak M, Fillmore C, Gao Y, Stanczyk F, Deng J, Sesterhenn I, Mostofi F, Fears T, Madigan M, Ziegler R, Fraumeni JJ, Hsing A. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10:421-427, 2001.
52. Chan J, Stampfer M, Ma J, Gann P, Gaziano J, Pollak M, Giovannucci E, Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94: 1099-1106, 2002.
53. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9, 2000.
54. 3 and its analog EB 1089. Int J Oncol 13:137-143, 1998.
55. 3. Prostate 26:72-79, 1995.
56. Martin JL, Pattison SL. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 141:2401-2409, 2000.
57. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-1324, 2001.
58. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res 83:1-54, 2001.
59. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA. Transforming growth factor-beta in benign and malignant prostate. Prostate 39:285-290, 1999.
60. Murthy S, Weigel N. 1a,25-Dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate (in press)
61. Tovar Sepulveda VA, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept 105:109-120, 2002.
62. Tovar Sepulveda VA, Falzon M. Regulation of PTH-related protein gene expression by vitamin D in PC-3 prostate cancer cells. Mol Cell Endocrinol 190:115-124, 2002.
63. Tovar Sepulveda VA, Falzon M. Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE. Mol Cell Endocrinol 204:51-64, 2003.
64. 3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:5091-5097, 2000.
65. 3 in prostate cancer cells. J Steroid Biochem Mol Biol 85:1-8, 2003.
66. DeSchrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen J. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63:3799-3804, 2003.
67. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-1212, 1999.
68. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071-2076, 1999.
69. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695-703, 1999.
70. Dunlap N, Schwartz GG, Eads D, Cramer SD, Sherk AB, John V, Koumenis C. 1Alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 89: 746-753, 2003.
71. Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 168:756-761, 2002.
72. 3. Endocrinology 136:20-26, 1995.
73. 2. Prostate 55:159-167, 2003.
74. 3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate 31:77-83, 1997.
75. 3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 59:4023-4029, 1999.
76. Hisatake J, O'Kelly J, Uskokovic MR, Tomoyasu S, Koeffler HP. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97:2427-2433, 2001.
77. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 3:1331-1338, 1997.
78. 3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Anticancer Res 19:1689-1697, 1999.
79. 3 analog combined with 9-cis retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 40:141-149, 1999.
80. 3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase. J Bone Miner Res 10:1951-1959, 1995.
81. 3. J Cell Biochem 88:267-273, 2003.
82. 3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 50:15-26, 2002.
83. 3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90:607-616, 2002.
84. 3 and prostate cancer cell proliferation in vivo. Urology 46:365-369, 1995.
85. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB 1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 60:779-782, 2000.
86. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8:241-248, 1999.
87. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50: 999-1006, 1997.
88. 3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 23:283-290, 2003.
89. 3. Chem Biol 6:265-275, 1999.
90. Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, Allegretto EA. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 49:224-233, 2001.
91. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 87:214-220, 2000.
92. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81:730-733, 1999.
93. Bernardi R, Johnson C, Modzelewski R, Trump D. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508-2514, 2002.
94. 3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 164: 133-143, 2000.
95. 3 (calcitriol). J Urol 159:2035-2039, 1998.
96. Beer T, Lemmon D, Lowe B, Henner W. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97:1217-1224, 2003.
97. Liu G, Oettel K, Ripple G, Staab MJ, Horvath D, Alberti D, Arzoomanian R, Mamocha R, Bruskewitz R, Mazess R, Bishop C, Bhattacharya A, Bailey H, Wilding G. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 8:2820-2827, 2002.
98. Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128, 2003.